Table 7 Performance of the four-marker model (IGF2+ IL6+ AFP+ platelet count) according to the BCLC, CLIP, and Okuda staging systems
Classification | AUC (95% Cl) | Sens% | Spe% | PPV% | NPV% | AC% |
|---|---|---|---|---|---|---|
Number of nodules (n, %) | ||||||
Single (67, 43.2%) | 0.95 (0.89-1.0) | 90 | 85 | 82 | 92 | 87 |
Multiple (88, 56.8) | 0.95 (0.88-1.0) | 90 | 85 | 82 | 92 | 87 |
Macro vascular invasion (n, %) | ||||||
Absent (141, 91%) | 0.94 (0.86-1.0) | 88 | 85 | 88 | 85 | 86 |
Present (14, 9%) | 1.0 (1.0-1.0) | 100 | 85 | 67 | 100 | 88 |
Size of nodules (n, %) | ||||||
< 2 (48, 31%) | 0.95 (0.87-1.0) | 92 | 85 | 85 | 92 | 88 |
> 2 (107, 69%) | 0.98 (0.93-1.0) | 94 | 85 | 88 | 92 | 99 |
BCLC stage (n, %) | ||||||
0-A (109, 70.3%) | 0.93 (0.96-1.0) | 83 | 85 | 83 | 85 | 84 |
B (46, 29.7) | 0.99 (0.96-1.0) | 100 | 85 | 80 | 100 | 91 |
CLIP stage (n, %) | ||||||
0-1 (122, 79%) | 0.94 (0.85-1.0) | 87 | 85 | 87 | 85 | 86 |
2-3 (33, 21%) | 1.0 (1.0-1.0) | 100 | 85 | 71 | 100 | 89 |
Okuda stage (n, %) | ||||||
Stage I (117, 75.5%) | 0.95 (0.88-1.0) | 92 | 85 | 86 | 92 | 89 |
Stage II (38, 24.5%) | 0.96 (0.87-1.0) | 86 | 85 | 75 | 92 | 85 |